SCHEDULE: Andreessen Horowitz Funds Sell Nautilus Biotechnology Shares

Major investment entities affiliated with Andreessen Horowitz have disclosed the sale of a substantial number of Nautilus Biotechnology shares, reducing their beneficial ownership.

Summary

• This filing is an amendment to a Schedule 13D, reporting changes in beneficial ownership of Nautilus Biotechnology, Inc. common stock by several entities and individuals associated with Andreessen Horowitz.
• The reporting persons include AH Bio Fund II, L.P., AH Equity Partners Bio II, L.L.C., Andreessen Horowitz LSV Fund II, L.P., AH Equity Partners LSV II, L.L.C., Marc Andreessen, and Benjamin Horowitz.
• Collectively, these entities and individuals have sold a significant number of shares in the period leading up to August 27, 2026.
• As of July 24, 2026, the total outstanding shares of Nautilus Biotechnology, Inc. common stock were reported as 127,255,223.
• The reporting persons collectively held 7,684,932 shares, representing 6.0% of the outstanding shares, prior to the recent sales.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to significant share sales by major holders, indicating a potential lack of confidence or a strategic shift away from the company.

Negatives

• Significant open market sales of Nautilus Biotechnology common stock were conducted by AH Bio II and AH LSV II between July 31, 2026, and August 27, 2026.
• AH Bio II sold a total of 1,375,500 shares during this period.
• AH LSV II sold a total of 114,499 shares during this period.
• These sales represent a notable reduction in the beneficial ownership of these major investment entities.

Risks

• The substantial sales by major investment entities could signal a decrease in confidence in the company's future prospects.
• Continued selling pressure from significant holders could negatively impact the stock price.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance from Nautilus Biotechnology, Inc. The information pertains to past transactions and current beneficial ownership.

Industry Context

StockSavvy.ai notes that significant share sales by prominent venture capital firms like Andreessen Horowitz can be interpreted by the market as a signal of reduced conviction in a company's growth trajectory or a realization of investment gains, potentially impacting investor sentiment across the biotechnology sector.

Stakeholder Impact

• Shareholders may experience negative price pressure due to the significant volume of shares sold by major holders.
• The reduction in ownership by prominent venture capital firms could affect investor confidence in the company's long-term strategy and growth potential.

Next Steps

• The reporting persons will continue to monitor their investments in Nautilus Biotechnology, Inc.
• Further transactions may be undertaken based on their ongoing review of the company's performance and market conditions.

Key Dates

Recommendation

The significant sales by major holders suggest a potential lack of conviction or a strategic exit, which is a negative indicator. However, the filing does not provide operational or financial performance data for Nautilus Biotechnology itself, making a definitive sell recommendation difficult without further analysis of the company's fundamentals. Therefore, a 'hold' position is advised pending more information on the company's performance and the rationale behind the sales.

Keywords

Nautilus Biotechnology, Schedule 13D, Andreessen Horowitz, Shareholder, Beneficial Ownership, Stock Sale, Venture Capital